Search Results

C4 Therapeutics, Inc. announced the closing of the previously announced $25 million stock purchase agreement with a wholly-owned subsidiary of Betta Pharmaceuticals Co. Ltd, a leading pharmaceutical company focusing on the development of innovative oncology therapies in China.

EyePoint Pharmaceuticals, Inc. today announced the execution of a license agreement with Betta Pharmaceuticals Co. Ltd. (SHE: 300558) to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau and Taiwan.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, today announced the closing of a $20 million equity investment, at $4.03 per share, by Betta Pharmaceuticals (SZ300558) bringing the total received to $35M . Betta is a top Chinese p

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.

Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.

Agenus Inc. announced that it has entered into an agreement with Betta Pharmaceuticals, a top Chinese pharmaceutical company focusing on the development of innovative oncology therapies, for an exclusive collaboration and license agreement for the development and commercialization of balstilimab and zalifrelimab in Greater China, including Mainland China, Hong Kong, Macau and Taiwan.